Related Experiment Video
Updated: Jul 17, 2026

Simplified Reverse Genetics Method to Recover Recombinant Rotaviruses Expressing Reporter Proteins
Published on: April 17, 2020
Rotarix (RIX4414): an oral human rotavirus vaccine
1Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Chile. moryan@med.uchile.cl
Insights
A new oral rotavirus vaccine, RIX4414, offers significant protection against severe gastroenteritis in young children. This vaccine is well-tolerated and not linked to intussusception, making it a safe option for infant immunization.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Rotavirus is a leading cause of severe gastroenteritis in children globally.
- Existing vaccines require improvement for early protection and safety, particularly regarding intussusception.
Purpose of the Study:
- To evaluate the efficacy, safety, and tolerability of the RIX4414 oral rotavirus vaccine in infants.
- To assess protection against common rotavirus serotypes and the risk of intussusception.
Main Methods:
- Phase I-III clinical trials involving over 70,000 children worldwide.
- Administration of two doses of RIX4414 between 6-24 weeks of age.
- Monitoring for vaccine reactogenicity, tolerability, and intussusception events.
Main Results:
- RIX4414 demonstrated high efficacy (85-96%) against moderate-to-severe rotavirus gastroenteritis.
- The vaccine was non-reactogenic, well-tolerated, and showed no association with intussusception.
- Hospitalizations due to gastroenteritis were reduced by over 40% in Latin America and 75% in Europe.
Conclusions:
- RIX4414 is a safe and effective oral rotavirus vaccine for infants.
- The vaccine provides robust protection against rotavirus gastroenteritis and reduces hospitalizations.
- RIX4414 meets the criteria for a valuable new tool in rotavirus disease prevention.
Abstract:
Rotavirus is the most common cause of severe gastroenteritis in children younger than 3 years of age worldwide. New rotavirus vaccine candidates were required to confer early protection against the most common rotavirus serotypes and to be well tolerated and not associated with intussusception. RIX4414 is a human-attenuated G1(P8) oral rotavirus vaccine administered in two doses at approximately 6-24 weeks of age. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses and the vaccination course should preferably be given before 16 weeks of age and must be completed, according to the manufacturer, by the age of 24 weeks. In a worldwide development program involving more than 70,000 children in six Phase I-III field trials, this vaccine proved to be nonreactogenic, well tolerated and not associated with intussusception. The vaccine provides over 85-96% protection against moderate-to-severe gastroenteritis caused by G1 and non-G1 serotypes, as demonstrated in Latin American and European clinical trial settings, respectively; and reduces gastroenteritis-related hospitalizations by more than 40% in Latin America and by 75% in European settings.
Related Concept Videos
Respiratory Syncytial Virus Disease
Poliomyelitis
Rabies
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Bacterial Gastroenteritis

